Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Einstein

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Expert Review of Anticancer Therapy|June 14, 2022
Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approvalHollis Viray, David F McDermott, David J Einstein
Current Opinion in Oncology|March 21, 2019
Targeting the androgen receptor and overcoming resistance in prostate cancerDavid J Einstein, Seiji Arai, Steven P Balk
Journal of General Internal Medicine|March 7, 2015
A Problematic Palsy: An Exercise in Clinical ReasoningDavid J Einstein, Robert L Trowbridge, Joseph Rencic
Journal of Palliative Medicine|May 19, 2015
Dying for Advice: Code Status Discussions between Resident Physicians and Patients with Advanced Cancer--A National SurveyDavid J Einstein, Katherine Levine Einstein, Paul Mathew
The Prostate|March 7, 2022
Immune mechanisms behind prostate cancer in men of African ancestry: A reviewDaniel Sentana-Lledo, Oliver Sartor, Steven P Balk, et al.
Urologic Oncology|February 8, 2023
Prevalence and Morbidity of Local Treatment-Related Side Effects in Metastatic Prostate Cancer PatientsDaniel Sentana-Lledo, Laura E Dodge, Peter Chang, et al.
Current Oncology Reports|February 22, 2025
Defining The Role for Hormone Therapy in Biochemically Recurrent Prostate Cancer: What Counts as a Win for Patients?Lauren O'Loughlin, Melissa L Abel, Ravi A Madan, et al.
Current Opinion in Oncology|April 4, 2024
Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patientsDavid J Einstein, Jeanny B Aragon-Ching, Fatima Karzai, et al.
The Oncologist|May 16, 2025
Days spent with healthcare contact by patients with metastatic castrate resistant prostate cancer in the last year of lifeDaniel Sentana-Lledo, Amelia Barnett, David J Einstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2024
Reply to B. Tombal et alDavid J Einstein, Meredith M Regan, Julia S Stevens, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Expert Review of Anticancer Therapy|June 14, 2022
Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approvalHollis Viray, David F McDermott, David J Einstein
Current Opinion in Oncology|March 21, 2019
Targeting the androgen receptor and overcoming resistance in prostate cancerDavid J Einstein, Seiji Arai, Steven P Balk
Journal of General Internal Medicine|March 7, 2015
A Problematic Palsy: An Exercise in Clinical ReasoningDavid J Einstein, Robert L Trowbridge, Joseph Rencic
Journal of Palliative Medicine|May 19, 2015
Dying for Advice: Code Status Discussions between Resident Physicians and Patients with Advanced Cancer--A National SurveyDavid J Einstein, Katherine Levine Einstein, Paul Mathew
The Prostate|March 7, 2022
Immune mechanisms behind prostate cancer in men of African ancestry: A reviewDaniel Sentana-Lledo, Oliver Sartor, Steven P Balk, et al.
Urologic Oncology|February 8, 2023
Prevalence and Morbidity of Local Treatment-Related Side Effects in Metastatic Prostate Cancer PatientsDaniel Sentana-Lledo, Laura E Dodge, Peter Chang, et al.
Current Oncology Reports|February 22, 2025
Defining The Role for Hormone Therapy in Biochemically Recurrent Prostate Cancer: What Counts as a Win for Patients?Lauren O'Loughlin, Melissa L Abel, Ravi A Madan, et al.
Current Opinion in Oncology|April 4, 2024
Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patientsDavid J Einstein, Jeanny B Aragon-Ching, Fatima Karzai, et al.
The Oncologist|May 16, 2025
Days spent with healthcare contact by patients with metastatic castrate resistant prostate cancer in the last year of lifeDaniel Sentana-Lledo, Amelia Barnett, David J Einstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2024
Reply to B. Tombal et alDavid J Einstein, Meredith M Regan, Julia S Stevens, et al.
Pageof 6